| [1] |
Wittenberger T, Sleigh S, Reisel D, et al. DNA methylation markers for early detection of women’s cancer: promise and challenges[J]. Epigenomics, 2014，6(2): 311-327.
|
| [2] |
孙可欣，郑荣寿，张思维，等.2015年中国分地区恶性肿瘤发病和死亡分析[J]．中国肿瘤，2019，11(2): 1-11.
|
| [3] |
Alix-Panabières C, Schwarzenbach H, Pantel K. Circulating tumor cells and circulating tumor DNA[J]. Annu Rev Med, 2012，63: 199-215.
|
| [4] |
Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer[J]. N Engl J Med，2013，368(13): 1199-1209.
|
| [5] |
Heitzer E, Auer M, Hoffmann EM, et al. Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer[J]. Int J Cancer, 2013，133(2): 346-356.
|
| [6] |
Lo YM, Zhang J, Leung TN, et al. Rapid clearance of fetal DNA from maternal plasma[J]．Am J Hum Genet, 1999, 64(1): 218-224.
|
| [7] |
Meric-Bernstam F, Mills GB. Overcoming implementation challenges of personalized cancer therapy[J]. Nat Rev Clin Oncol, 2012，9(9): 542-548.
|
| [8] |
Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer[J]. Clin Chem, 2015，61(1): 112-123.
|
| [9] |
Thierry AR, Mouliere F, El Messaoudi S, et al.Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA[J]. Nat Med, 2014，20(4): 430-435.
|
| [10] |
Bettegowda C, Sausen M, Leary RJ, et al.Detection of circulating tumor DNA in early- and late-stage human malignancies[J]. Sci Transl Med, 2014，6(224): 224-225.
|
| [11] |
Chan KC, Jiang P, Chan CW, et al.Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing[J]. Proc Natl Acad Sci U S A, 2013，110(47): 18 761-18 768.
|
| [12] |
Chen X. Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer[J]. Clin Cancer Res, 1999，5(9): 2297-2303.
|
| [13] |
Chan KC, Jiang P, Zheng YW, et al.Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing[J]. Clin Chem, 2013，59(1): 211-224.
|
| [14] |
McBride DJ, Orpana AK, Sotiriou C, et al. Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors[J]．Genes Chromosomes Cancer, 2010, 49(11): 1062-1069.
|
| [15] |
Leary RJ, Sausen M, Kinde I, et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing[J]. Sci Transl Med, 2012，4(162): 162ra154.
|
| [16] |
Diehl F, Schmidt K, Choti MA, et al.Circulating mutant DNA to assess tumor dynamics[J]. Nat Med, 2008，14(9): 985-990.
|
| [17] |
Shaw JA, Page K, Blighe K, et al.Genomic analysis of circulating cell-free DNA infers breast cancer dormancy[J]. Genome Res, 2012，22(2): 20-31.
|
| [18] |
Mohan S, Heitzer E, Ulz P, et al.Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing[J]. PLoS Genet, 2014，10(3): e1004271.
|
| [19] |
Schmitt MW, Kennedy SR, Salk JJ, et al.Detection of ultra-rare mutations by next-generation sequencing[J]. Proc Natl Acad Sci U S A, 2012，109(36): 14508-14513.
|
| [20] |
Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer[J]. N Engl J Med, 2008，359(17): 1757-1765.
|
| [21] |
Nik-Zainal S, Alexandrov LB, Wedge DC, et al. Mutational processes molding the genomes of 21 breast cancers[J]. Cell, 2012，149(5): 979-993.
|
| [22] |
Nik-Zainal S. The life history of 21 breast cancers[J]. Cell, 2012，149(5): 994-1007.
|
| [23] |
Nik-Zainal S, Davies H, Staaf J, et al.Landscape of somatic mutations in 560 breast cancer whole-genome sequences[J]. Nature, 2016，534(7605): 47-54.
|
| [24] |
Bosch A, Li Z, Bergamaschi A, Ellis H, et al.PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer[J]. Sci Transl Med, 2015, 7(283): 283ra51.
|
| [25] |
Schiavon G, Hrebien S, Garcia-Murillas I, et al.Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer[J]. Sci Transl Med, 2015, 7(313): 313ra182.
|
| [26] |
Alix-Panabières C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy[J]. Cancer Discov, 2016，6(5): 479-491.
|
| [27] |
Oshiro C, Kagara N, Naoi Y, et al.PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients[J]. Breast Cancer Res Treat, 2015，150(2): 299-307.
|
| [28] |
Hultsch S, Kankainen M, Paavolainen L, et al.Association of tamoxifen resistance and lipid reprogramming in breast cancer[J]. BMC Cancer, 2018，18(1): 850.
|
| [29] |
Olsson E, Winter C, George A, et al.Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease[J]. EMBO Mol Med, 2015，7(8): 1034-1047.
|